Nirsevimab: The Hidden Costs

被引：4
|
作者：
Neumann, Samantha [1 ,2 ]
Alverson, Brian [1 ,2 ]
机构：
[1] Nemours Childrens Hlth, Wilmington, DE USA
[2] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA USA
来源：
HOSPITAL PEDIATRICS | 2024年 / 14卷 / 06期
关键词：
RESPIRATORY SYNCYTIAL VIRUS; INFANTS; RSV;
D O I：
10.1542/hpeds.2024-007739
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
[No abstract available]
引用
收藏
页码：e276 / e278
页数：3
相关论文
共 50 条
  • [41] Nirsevimab-a breakthrough in respiratory syncytial virus bronchiolitis
    Assad, Zein
    Papenburg, Jesse
    Ouldali, Naim
    LANCET CHILD & ADOLESCENT HEALTH, 2024, 8 (10) : 708 - 709
  • [42] Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain
    Ruiz, Sara Jimeno
    Pelaez, Adrian
    Labourt, Agustin
    Acuna, Florencia Mercedes
    Linares, Lucia
    Martin, Isabel Llana
    Gomez, Angeles Calle
    Martinez, Silvina Natalini
    VACCINES, 2024, 12 (10)
  • [43] Nirsevimab-resistant respiratory syncytial virus strains are rare but there
    Peeples, Mark, I
    Thongpan, Ilada
    LANCET INFECTIOUS DISEASES, 2023, 23 (07) : 773 - 774
  • [44] Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1685): : 145 - 148
  • [45] Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper
    Esposito, Susanna
    Abu-Raya, Bahaa
    Bonanni, Paolo
    Cahn-Sellem, Fabianne
    Flanagan, Katie L.
    Martinon Torres, Federico
    Mejias, Asuncion
    Nadel, Simon
    Safadi, Marco A. P.
    Simon, Arne
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [46] Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
    Griffin, M. Pamela
    Yuan, Yuan
    Takas, Therese
    Domachowske, Joseph B.
    Madhi, Shabir A.
    Manzoni, Paolo
    Simoes, Eric A. F.
    Esser, Mark T.
    Khan, Anis A.
    Dubovsky, Filip
    Villafana, Tonya
    DeVincenzo, John P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (05) : 415 - 425
  • [47] Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)
    Bergeron, Harrison C.
    Tripp, Ralph A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (01) : 23 - 29
  • [48] Cost-effectiveness of nirsevimab and maternal RSVpreF for preventing respiratory syncytial virus disease in infants across Canada
    Bugden, Samara
    Mital, Shweta
    Nguyen, Hai V.
    BMC MEDICINE, 2025, 23 (01):
  • [49] Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
    Hammitt, Laura L.
    Dagan, Ron
    Yuan, Yuan
    Cots, Manuel Baca
    Bosheva, Miroslava
    Madhi, Shabir A.
    Muller, William J.
    Zar, Heather J.
    Brooks, Dennis
    Grenham, Amy
    Hamren, Ulrika Wahlby
    Mankad, Vaishali S.
    Ren, Pin
    Takas, Therese
    Abram, Michael E.
    Leach, Amanda
    Griffin, M. Pamela
    Villafana, Tonya
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (09) : 837 - 846
  • [50] Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in France
    de Sentuary, Charlotte Ocana
    Testard, Clara
    Lagree, Marion
    Leroy, Maxime
    Gasnier, Lisa
    Enes-Dias, Alicia
    Leruste, Constance
    Diallo, Diariatou
    Genin, Michael
    Rakza, Thameur
    Dubos, Francois
    ECLINICALMEDICINE, 2025, 79
12345